Evidence map›Paper›PMID 34729224›Full record

ArticleCentral European journal of urology2021

Is ERCC1 a prognostic biomarker for urothelial cancer following radical cystectomy? A long-term analysis.

Mateusz Obarzanowski, Janusz Kopczynski, Jaroslaw Jaskulski, Antoni Domagala, Pawel Macek, Stanislaw Gozdz, Maciej Salagierski

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Central European journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mateusz ObarzanowskiInstitute of Medical Scienes, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Janusz KopczynskiInstitute of Medical Scienes, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Jaroslaw JaskulskiInstitute of Medical Scienes, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Antoni DomagalaInstitute of Medical Scienes, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Pawel MacekInstitute of Medical Scienes, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Stanislaw GozdzInstitute of Medical Scienes, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Maciej SalagierskiDepartment of Urology, Collegium Medicum, University of Zielona Góra, Poland.
Holy Cross University · PLJan Kochanowski University · PLUniversity of Zielona Góra · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionExcision repair cross-complementation 1 protein (ERCC1) plays a vital role in cancer cells enabling DNA repair via nucleotide excision repair. Thus, we hypothesized whether expression of this protein may be utilized as a prognostic marker in patients after radical cystectomy. MATERIAL AND

methodsThe final analysis involved 123 patients with urothelial bladder carcinoma who underwent radical cystectomy with bilateral lymphadenectomy. The median follow-up time was equal to 853 days. ERCC1 status was evaluated immunohistochemically with the application of tissue microarrays.

resultsPositive ERCC1 expression was noted in 46% of the studied cases. Among the analyzed clinical and pathological factors, we could not establish a statistically significant correlation with ERCC1. Similarly, survival curves were statistically indifferent in patients with tumors categorized according to both expression categories. We did not confirm a prognostic value of ERCC1 in the multivariate regression analysis.

conclusionsERCC1 expression does not influence the overall survival of patients with urothelial bladder carcinoma after radical cystectomy.

Indexed as

bladder cancerERCC1 expressionradical cystectomyurothelial carcinoma

Identifiers

PMID34729224
PMCPMC8552925
OpenAlexW3209950047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.